Form 8-K - Current report:
SEC Accession No. 0001193125-18-040290
Filing Date
2018-02-12
Accepted
2018-02-12 16:47:04
Documents
1
Period of Report
2018-02-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K d514475d8k.htm 8-K 23761
  Complete submission text file 0001193125-18-040290.txt   25339
Mailing Address 315 MADISON AVENUE 4TH FLOOR NEW YORK NY 10017
Business Address 315 MADISON AVENUE 4TH FLOOR NEW YORK NY 10017 (813) 864-4523
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 18597157
SIC: 2834 Pharmaceutical Preparations